miReven is a biopharmaceutical company focused on developing mRx-7 as a new cancer therapy. The world of RNA-based therapeutics is an entirely new clinical treatment
mRx-7 is a synthetic small double stranded RNA (dsRNA) chemically modified mimic of microRNA-7 (miR-7) that we have designed, which is a potent inhibitor of…
miReven welcomes new partnerships Please contact us for information about investing in our company
microRNAs are tiny molecules that are encoded in the DNA within our cells. They are responsible for controlling expression of genes that dictate how the cell behaves, including deciding when to divide or move. In some cancers the amount of
Prof Peter Leedman presented the latest promising results of mRx-7 at the Functional Nucleic Acid…
miReven scientists evaluate microRNA-7 delivery in preclinical models and methods for quantitation and publish in…
miReven scientists publish paper in prestigious journal Hepatology identifying new pathways that mediate resistance to…
